Patient Satisfaction And Spectacle Independence With Two Presbyopia Correcting Iols

To report the patient satisfaction and spectacle independence data in patients successfully implanted with the wavefront shaping AcrySof Vivity IOL (Alcon) or the trifocal AcrySof PanOptix IOLs (Alcon) toric and non-toric. PanOptix has proven excellent visual acuity at distance, intermediate and near, high spectacle independence, and good patient satisfaction. Vivity is a relatively new PCIOL promising good distance, intermediate vision and functional near vision. 

Optalmica Eyeclinics, Sweden. Private clinics. Single surgeon. Immediate subsequent bilateral implantation in a real world setting through routine clinical practice from October 2020 to December 2021. The questionnaire is part of the routine clinical practice at one month post-surgery.

Patient satisfaction, spectacle independence and visual disturbances were recorded via a questionnaire at one month follow-up visit post- surgery. The questionnaire has a 79,3% frequency of answer. Cataract and RLE patients are included and emmetropia was targeted for both eyes. Healthy eyes were included and in the Vivity group also eyes with very small pigmentary changes in macula. Patient’s age was 64 ± 19 years and 62 ± 15 years for the Vivity and PanOptix group respectively. Patient selection for each IOL was done on individual basis together with the patient, based on patient expectation and clinical assessments. Patients with high demands of spectacle freedom at near received for example the trifocal IOL.

To date we have the one-month data for 140 Vivity patients and 44 PanOptix patients.

Patient satisfaction overall with the outcome: Vivity 100 %, PanOptix 94 % satisfied

Distance vision (good/medium/dissatisfactory): Vivity 100% good, PanOptix 94/6/0 %

Intermediate vision/computer distance (good/medium/dissatisfactory): Vivity 87/9/4%, PanOptix 84/4/12 %

Near vision (good/medium/dissatisfactory): Vivity 77/13/10 %, PanOptix 96/0/4 %

Bother by light disturbances (never/occasionally/a lot): Vivity 75/23/2 %, PanOptix 33/48/19 %

Spectacle usage (never/occasionally/frequently): Vivity 63/33/4 %, PanOptix 88/12/0 %

Patients are satisfied and experience a good distance vision with both the trifocal and the wavefront shaping IOL. The Vivity IOL only promises functional near vision but 77% report good vision at near and as many as 96% of the patients report never or only sometimes needing spectacles. The level of visual disturbances is low for the Vivity and higher for PanOptix, which was expected since PanOptix, is a trifocal IOL and may need more time for neural adaptation.